William K. Schmidt

Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA.

Renovis, Inc. develops pharmaceutical products. The company discovers, develops, and commercializes novel therapeutics for neurological and inflammatory diseases. It is headquartered in San Francisco, CA

Signature Therapeutics, Inc. develops and manufactures pharmaceutical products. It focuses on developing medications for use in pain management and ADHD. Its proprietary BIO-MD platform is designed to deter prescription drug abuse by virtue of strong chemical bonds within the prodrug and also offers solution to the ongoing epidemic of prescription opioid drug abuse. The company was founded by Steven L. Shafer in 2004 and is headquartered in Palo Alto, CA.

Arcion Therapeutics LLC develops topical therapies for chronic pain. The firm offers innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Its product pipeline comprises multiple candidates to treat neuropathic pain, a complex and debilitating form of chronic pain. The company is headquartered in Baltimore, MD.

Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities.

The Eastern Pain Association operates as health care association which provides pain control services. The company was founded in 1974 by Berthold B. Wolff and is headquartered in Gainesville, FL.